Official Title: “Effect of Montelukast on the Airway Remodeling in Asthma Patients: Physiological-Radiological Correlation”

The distal lung contributes to asthmatic airway remodeling which is observed from early onset of the disease. Cysteinyl leukotrienes (CysLT) play important role in the pathogenesis of airway remodeling and antileukotrienes work to exert a certain degree of anti-inflammatory effect. The cysteinyl leukotriene antagonist Montelukast has been in vivo shown to significantly inhibit ovalbumin induced airway smooth muscle hyperplasia and subepithelial fibrosis in sensitized mice. This study aims to evaluate if Montelukast could reverse airway remodeling in asthma patients by a non-invasive approach-HRCT.

Study Type: Interventional

Study Design: Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study

Study Primary Completion Date: October 2010

Accumulated data have suggested that the distal lung, which includes airways of < 2mm in diameter and lung parenchyma, contribute to asthma pathogenesis and symptoms. In addition to persisting inflammation, distal lung undergoes remodeling, as demonstrated by the reduced elastic fiber content and abnormal alveolar attachments, with the latter thought to result in a loss of elastic recoil and a reduction in FEV1.0. Furthermore, recent studies have shown that airway remodeling is observed from early onset of the disease and may, therefore, be characteristic of asthma. Amounting evidence has revealed that airway remodeling of asthmatic airways accounts for a large component of airway hyperresponsiveness (AHR) and excessive airway narrowing.

Since remodeling processes occur in parallel to, or may even be obligatory for, the establishment of persistent inflammation, the pathogenesis of airway remodeling and the implications of therapeutic interventions that are designed to diminish airway remodeling remain important areas of both research and clinic. Inhale corticosteroid (ICS) is mainstay for the treatment of asthma, however, ICS provides very little benefit for airway remodeling.

Cysteinyl leukotrienes (CysLT) play important role in the pathogenesis of airway remodeling and antileukotrienes work to exert a certain degree of anti-inflammatory effect. The cysteinyl leukotriene antagonist Montelukast, for example, has been in vivo shown to significantly inhibit ovalbumin induced airway smooth muscle hyperplasia and subepithelial fibrosis in sensitized mice. Montelukast, a systemically delivered leukotriene receptor antagonist, has been strongly recommended to treat asthma by several guidelines. Clinically, the systemically acting oral agent montelukast has been shown to improve proximal and distal lung physiology. In particular, improvements in distal lung function correlate with improvements in asthma symptoms. The in vivo experiments performed in rodent animal challenged by OVA have shown that Montelukast can reverse airway remodeling, as well as inhibit inflammation.

To determine the occurrence of airway remodeling in human being, bronchial biopsy samples obtained with a bronchoscope are subjected to histological examination. However, bronchial biopsy is invasive and causes considerable pain, while assessment of the peripheral small airways and of changes in the deep submucosal tissue and airway smooth muscle in large airways is technically difficult. This technique does not allow the longitudinal analysis of airway wall dimensions.

Noninvasive evaluation of airways by means of imaging with high-resolution computed tomography (HRCT) has therefore been tried as an alternative procedure, and was found to have the potential to evaluate airways in patients with obstructive pulmonary disease. The measurement of airway wall thickness by HRCT in patients with asthma has been demonstrated to correlate with the severity of asthma. Computed tomographic imaging of the airways by HRCT has been widely applied to investigate the alterations in the structure of the airways termed airway remodeling in patients with airway obstructive diseases (see references 1-4).

So far to our knowledge, there is no study aiming to evaluate if Montelukast could reverse airway remodeling in asthma patients by HRCT.

Our encouraging preliminary data performed in 4 patients with moderate to severe asthma according to GINA definition who received oral Montelukast for 3 months demonstrate with or without combination of ICS+LABA that there were significant improvements in airway wall thickness and air trapping evaluated by measurement of HRCT and lung function in patients with oral Montelukast as compared with those without oral Montelukast. We adopted WA% and WA/BSA to reflect the degree of airway thickness as published methods. We found that the patients who received oral montelukast for 3 months experienced improvements in airway remodeling. WA/BSA and WA% significantly decreased compared to the baseline.

The purpose of the proposal presented is to further examine, in a relatively large number of patients, that Montelukast can improve the structural changes in the large airways and air trapping by means of HRCT, and their relationship with pulmonary function in patients in moderate to severe asthma.

Intervention(s) in this Clinical Trial

• Drug: leukotriene receptor antagonist (montelukast)
  • leukotriene receptor antagonist montelukast 10mg, QN, 6 months
• Drug: placebo
  • placebo, 10mg, QN, 6 months

Arms, Groups and Cohorts in this Clinical Trial

• Placebo Comparator: P
  • The patients in this placebo comparator arm will receive inhale corticosteroid plus long-acting bronchodilator and placebo for 6 months.
• Experimental: T
  • The patients in this placebo comparator arm will receive inhale corticosteroid plus long-acting bronchodilator and montelukast for 6 months

Primary Measures

• Montelukast can improve lung function including proximal and distal airways and reverse airway remodeling in moderate to severe patients with asthma.
  • Time Frame: 6 months
    Safety Issue?: Yes

Secondary Measures

• Montelukast can bring additional benefit for lung function improvement in moderate to severe patients with asthma
  • Time Frame: 6 months
    Safety Issue?: Yes

Inclusion Criteria:

• forced expiratory volume in one second (FEV1) is at 60-80% predicted or less than 60% predicted
• clinical diagnosis of moderate-to-severe asthma.

Exclusion Criteria:

• intravenous, oral or intramuscular steroids used within 1 months
• Anti-leukotrienes, cromolyn sodium or nedocromil used within 2 months
• Theophylline or beta-adrenergic blockers used within 1 month
• Tobacco Used within the past year or cumulative smoking history > 5 pack-yrs
• Respiratory infection or an influenza vaccination Within 3 weeks
• Pregnant or lactating females
• Patient has a history of an anaphylactic allergic reaction related to administration of either a marketed or investigational drug

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 16 Years

Maximum Age for this Clinical Trial: 65 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: Chinese Academy of Medical Sciences

Overall Clinical Trial Officials and Contacts

Jinming Gao, M.D., Ph.D. Principal Investigator Peking Union Medical College Hospital  

Overall Contact: Jinming Gao, M.D., Ph.D. 86-10-6529-5035 gjinming@yahoo.com

Information obtained from ClinicalTrials.gov on October 10, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00699062

Study ID Number: JGao001

ClinicalTrials.gov Identifier: NCT00699062

Health Authority: China: Ethics Committee

this website provides the updated information on the this study